At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 172 enrolled
Drug / intervention
Pemetrexed +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Carcinoma
In Brief
A Phase 2 clinical trial evaluating Pemetrexed, Cisplatin, and 1 other intervention for Non-Small-Cell Lung Carcinoma. Completed, enrolled 172 participants across 44 sites in 12 countries.
Detailed Summary
The primary purpose of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced nonsquamous non-small cell lung carcinoma (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small-Cell Lung Carcinoma
CountriesArgentina, Belgium, Brazil, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartApr 2011
Primary CompletionJan 2013
Study CompletionJun 2016
TodayJul 2026
First PostedNov 2, 2010
Enrollment StartApr 1, 2011
Primary CompletionJan 1, 2013
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.7 years ago
Interventions
Pemetrexeddrug
Administered intravenously (IV)
Cisplatindrug
Administered IV
Cixutumumabdrug
Administered IV